openPR Logo
Press release

direct/ Crucell N.V. (NL) - PRESS EVENT - Crucell invites you to witness the construction of a unique process technology center

09-21-2006 01:17 PM CET | Health & Medicine

Press release from: Crucell N.V. (NL)

Crucell is pleased to invite you to witness a unique event - the construction of the Valerio Building - the only building of its kind in the world. Named after Crucell´s co-founder Dinko Valerio, the Valerio Building will be a state-of-the-art facility. The core of the facility consists of 64 modules that have been constructed off-site in Germany. Each module measures roughly 17.5 x 5.0 x 4.0 m (LxWxH) and the total weight of all modules is 1800 ton. These modules will be transported from Germany to Leiden via ship and truck and then ´stacked´ to form the completed building.

There will be a Press Briefing at 11:00 on 2 October 2006 to give background information about the transportation of the modules, details on the building, what it will be used for and what makes it so unique. The first module will be placed at 07:00 on 5 October 2006. Journalists and photographers are welcome to attend at this time.

Both events will take place at Crucell´s headquarters:
Archimedesweg 4
2333 CN Leiden

Crucell is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell´s core portfolio includes vaccines against hepatitis B and influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden, with subsidiaries in Switzerland, Spain, Italy and Korea. The Company employs about 900 people. Crucell is currently listed on Euronext, NASDAQ and the Swiss Exchange.

FOR FURTHER INFORMATION, PLEASE DOWNLOAD THE FOLLOWING PDF FILE:

Invitation



The announcement distributed by directnews.
The issuer is solely responsible for the content of this announcement.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release direct/ Crucell N.V. (NL) - PRESS EVENT - Crucell invites you to witness the construction of a unique process technology center here

News-ID: 11411 • Views:

More Releases from Crucell N.V. (NL)

direct/ Crucell N.V. (NL): Crucell Licenses STAR(TM) Technology to XOMA for Rese …
Leiden, The Netherlands, January 5, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a non-exclusive STAR(TM) research license agreement for the production of monoclonal antibodies and other proteins with Berkeley, California-based XOMA Ltd. (NASDAQ: XOMA). Financial details were not disclosed. "XOMA regularly evaluates technologies that can help us stay at the cutting edge of antibody and recombinant protein technology," said Jack Castello,
direct/ Crucell N.V. (NL) - Crucell Announces PER.C6(R) Licensing Agreement with …
Leiden, The Netherlands, December 8, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a PER.C6® research license agreement with German vaccine development company Vakzine Projekt Management (VPM) GmbH. The non-exclusive agreement allows VPM to use the PER.C6® cell line to develop a vaccine to prevent a specific (undisclosed) infectious disease, and to develop diagnostics. VPM has also obtained an option to convert
Crucell N.V. (NL) - Crucell Appoints Agents to Boost Asian Market Potential
Leiden, The Netherlands, September 20, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has entered into agreements with Pharma&Soft in South Korea and Biott in Japan to increase the licensing business for PER.C6® and Advac® technology in Asia. Under the contracts, the two agencies shall help Crucell to contact and secure agreements with prospective Korean and Japanese PER.C6® and Advac® licensees for the development

All 4 Releases


More Releases for Valerio

Metastatic Prostate Cancer Clinical and Non-Clinical Studies, Key Companies, The …
Metastatic Prostate Cancer Pipeline constitutes 80+ key companies continuously working towards developing 85+ Metastatic Prostate Cancer treatment therapies, analyzes DelveInsight. Metastatic Prostate Cancer Overview: Metastatic prostate cancer is an advanced stage of the disease where cancer cells from the prostate gland spread to other parts of the body, often through the bloodstream or lymphatic system. It poses a significant clinical challenge as it can affect vital organs like bones, lymph nodes, liver,
The documentary HOMELESS premiered in Cairo (Egypt) at the World Urban Forum, an …
The prestigious conference provided the perfect platform for the film's debut, as it brought together leaders, policymakers, experts and advocates from around the globe to address issues related to urbanization, sustainable development, and social inclusion. UN-Habitat will use HOMELESS to promote its World Urban Campaign and #HousingMatters Campaign, which shine a light on the urgent need for safe and affordable housing for all. At the world premiere of HOMELESS, Christine Auclair,
Metastatic Prostate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, …
DelveInsight's, "Metastatic Prostate Cancer Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in metastatic prostate cancer pipeline landscape. It covers the Metastatic Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest
Metastatic Prostate Cancer Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMD …
DelveInsight's, "Metastatic Prostate Cancer Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in metastatic prostate cancer pipeline landscape. It covers the Metastatic Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest
eXact learning solutions releases ‘con-X’, new functionality for greater eng …
eXact learning solutions, the leading, global, ‘knowledge-transfer’ (LCMS) technology provider, is launching ‘con-X’, a new innovation to increase engagement across organisations, and transform knowledge-based content sharing. This new addition to the product suite aims to increase overall engagement rates and vastly improve RoI for a range of change initiatives. con-X increases user engagement by allowing continuous feedback loops with key stakeholders. This will allow organizations to adjust, manage and improve knowledge-based
Evidence emerges that the European market is waking up to the benefits of an LCM …
Visitors to its booth at Learning Technologies in London raised five key issues with the digital learning content management business solutions producer, eXact learning solutions. “Overall, the Learning Technologies event in London’s Olympia, attracted its usual crop of several thousand visitors – mostly from around Europe - and our records show that many of them visited the eXact learning solutions’ booth,” said Valerio Torda, the company’s managing director. According to eXact learning